Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
- 27 April 2021
- journal article
- letter
- Published by Elsevier BV in Annals of Oncology
- Vol. 32 (8), 1053-1055
- https://doi.org/10.1016/j.annonc.2021.04.019
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 InfectionJAMA Oncology, 2021
- Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional surveyAnnals of Oncology, 2021
- Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE studyAnnals of Oncology, 2011
- Response to influenza virus vaccination during chemotherapy in patients with breast cancerAnnals of Oncology, 2011